Friday, 16 October 2026European Markets

SALMONES CAMANCHAC, BONDUELLE, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - salmones camanchac (sacam.ol) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
salmones camanchac (sacam.ol) kr32.00 11.2% 3.92%
bonduelle (bon.pa) €10.66 2.35% 1.08%
glanbia plc (gl9.ir) €15.74 2.17% 13.35%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. salmones camanchac (sacam.ol)

11.2% forward dividend yield and 3.92% return on equity

salmones camanchaca s.a. engages in the salmon farming business in chile. the company offers atlantic and coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. it also exports its products. the company was incorporated in 2009 and is based in puerto montt, chile. salmones camanchaca s.a. is a subsidiary of compañía pesquera camanchaca s.a.

earnings per share

as for profitability, salmones camanchac has a trailing twelve months eps of kr1.17.

pe ratio

salmones camanchac has a trailing twelve months price to earnings ratio of 27.35. meaning, the purchaser of the share is investing kr27.35 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.92%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on apr 28, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 11.2%.

moving average

salmones camanchac's worth is under its 50-day moving average of kr34.93 and way under its 200-day moving average of kr40.29.

more news about salmones camanchac.

2. bonduelle (bon.pa)

2.35% forward dividend yield and 1.08% return on equity

bonduelle sca produces, processes, and sells vegetables and fruits in europe and internationally. the company offers canned, frozen, fresh cut, and ready to eat vegetables, as well as packaged and prepared ready to eat vegetable salads; and salad bowls, meals, ready-to-mix salads, value-added vegetables, etc. it provides its products under the bonduelle, cassegrain, del monte, arctic gardens, globus, and ready pac foods brands, as well as private labels. the company was founded in 1853 and is headquartered in renescure, france.

earnings per share

as for profitability, bonduelle has a trailing twelve months eps of €0.27.

pe ratio

bonduelle has a trailing twelve months price to earnings ratio of 39.48. meaning, the purchaser of the share is investing €39.48 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.08%.

volume

today's last reported volume for bonduelle is 1682 which is 89.05% below its average volume of 15370.

more news about bonduelle.

3. glanbia plc (gl9.ir)

2.17% forward dividend yield and 13.35% return on equity

glanbia plc operates as a nutrition company worldwide. the company manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, online, and gyms, as well the food, drug, mass, and club channels. it also engages in the manufacture and sale of cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes. in addition, the company engages in the financing, research and development, property and land dealing, receivables management, management, property leasing, business service, weight management, and bioactive solutions businesses. it operates a portfolio of brands, including optimum nutrition, bsn, isopure, nutramino, slimfast, think!, amazing grass, body & fit, and levlup brands. glanbia plc was founded in 1964 and is headquartered in kilkenny, ireland.

earnings per share

as for profitability, glanbia plc has a trailing twelve months eps of €0.89.

pe ratio

glanbia plc has a trailing twelve months price to earnings ratio of 17.69. meaning, the purchaser of the share is investing €17.69 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.35%.

yearly top and bottom value

glanbia plc's stock is valued at €15.74 at 01:30 est, under its 52-week high of €16.04 and way higher than its 52-week low of €11.01.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, glanbia plc's stock is considered to be oversold (<=20).

moving average

glanbia plc's value is above its 50-day moving average of €15.27 and way higher than its 200-day moving average of €14.05.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on aug 24, 2023, the estimated forward annual dividend rate is 0.34 and the estimated forward annual dividend yield is 2.17%.

more news about glanbia plc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com